Repositioning HIV protease inhibitors as cancer therapeutics

Purpose of reviewAlthough designed to target only the HIV protease, HIV protease inhibitors induce toxicities in patients such as insulin resistance and lipodystrophy that suggest that protease inhibitors have other targets in mammalian cells. Akt controls insulin signaling and is an important target in cancer, but no Akt inhibitors are approved as cancer therapeutics. These observations have prompted the study of HIV protease inhibitors as inhibitors of Akt and possible cancer therapeutics. This review will highlight the latest advances in repositioning HIV protease inhibitors as cancer therapeutics. Recent findingsAlthough protease inhibitors can inhibit Akt activation and the proliferation of over 60 cancer cell lines, as well as improve sensitivity to radiation or chemotherapy, these effects do not always correlate with Akt inhibition. Other important processes, such as the induction of endoplasmic reticulum stress, appear critical to the biological activity of protease inhibitors. These impressive and surprising preclinical data have prompted clinical testing of nelfinavir as a lead HIV protease inhibitor in cancer patients. SummaryAlthough mechanisms of action for the antitumor effects of HIV protease inhibitors are complex, their broad spectrum of activity, minimal toxicity, and wide availability make protease inhibitors ideal candidates for repositioning as cancer therapeutics.

[1]  M. Mostert,et al.  The HIV Protease Inhibitors Nelfinavir and Saquinavir, but Not a Variety of HIV Reverse Transcriptase Inhibitors, Adversely Affect Human Proteasome Function , 2005, Antiviral therapy.

[2]  Rosemarie Mick,et al.  Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. , 2003, International journal of radiation oncology, biology, physics.

[3]  O. Trygstad,et al.  Generalized lipodystrophy, congenital and acquired (lipoatrophy) , 1996, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[4]  W. Travis,et al.  Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Kaufman,et al.  From acute ER stress to physiological roles of the Unfolded Protein Response , 2006, Cell Death and Differentiation.

[6]  Amalio Telenti,et al.  CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.

[7]  M. Reitz,et al.  Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. , 2002, Blood.

[8]  Y. Ohtsuki,et al.  HIV-1 Protease Inhibitor , Ritonavir : A Potent Inhibitor of CYP 3 A 4 , Enhanced the Anticancer Effects of Docetaxel in Androgen-Independent Prostate Cancer Cells In vitro and In vivo , 2004 .

[9]  Y. Ohtsuki,et al.  HIV-1 Protease Inhibitor, Ritonavir , 2004, Cancer Research.

[10]  F. Goebel,et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.

[11]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[12]  A. Rudich,et al.  Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors , 2003, AIDS.

[13]  M. Lederman,et al.  In vivo analysis of Fas/FasL interactions in HIV-infected patients. , 1998, The Journal of clinical investigation.

[14]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[15]  Theresa M. Grana,et al.  Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. , 2002, Cancer research.

[16]  H. Koeffler,et al.  NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines , 2006, British Journal of Cancer.

[17]  A. Rudich,et al.  Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-ζ , 2004, Diabetologia.

[18]  H. Koeffler,et al.  HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. , 2004, Molecular cancer therapeutics.

[19]  D. Cooper,et al.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.

[20]  R. Grant,et al.  Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. , 2000, The Journal of infectious diseases.

[21]  D. Nowis,et al.  Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. , 2004, Oncology reports.

[22]  Y. Ohtsuki,et al.  HIV‐1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling , 2005, Cancer science.

[23]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[24]  P. Monini,et al.  Antitumour effects of antiretroviral therapy , 2004, Nature Reviews Cancer.

[25]  M. Schütt,et al.  Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. , 2004, The Journal of endocrinology.

[26]  S. Hahn,et al.  Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. , 2006, Cancer research.

[27]  S. Hahn,et al.  The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. , 2007, Neoplasia.

[28]  C. Vigouroux,et al.  The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. , 2001, Diabetes.

[29]  W. Rozenbaum,et al.  Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance , 2002, The Lancet.

[30]  C. Galanos,et al.  Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. , 2002, Cancer research.

[31]  K. Flaherty,et al.  HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. , 2007, Cancer research.

[32]  S. Levitz.  Improvement in CD4+ cell counts despite persistently detectable HIV load. , 1998, The New England journal of medicine.

[33]  W. Rozenbaum,et al.  Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). , 1999, Diabetes & metabolism.

[34]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[35]  M. Bogyo,et al.  How an Inhibitor of the HIV-I Protease Modulates Proteasome Activity* , 1999, The Journal of Biological Chemistry.

[36]  S. Hahn,et al.  Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. , 2007, Cancer research.

[37]  Thomas C Chen,et al.  Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. , 2007, Neurosurgical focus.

[38]  Ana Maria Cuervo,et al.  Autophagy: Many paths to the same end , 2004, Molecular and Cellular Biochemistry.

[39]  Rosemarie Mick,et al.  HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. , 2005, Cancer research.

[40]  Junying Yuan,et al.  Cellular response to endoplasmic reticulum stress: a matter of life or death , 2006, Cell Death and Differentiation.

[41]  Frank Pajonk,et al.  The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. , 2002, Cancer research.

[42]  C. Flexner,et al.  Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors* , 2000, The Journal of Biological Chemistry.

[43]  C. Thompson,et al.  Putting the rap on Akt. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Hallahan,et al.  HIV protease inhibitors enhance the efficacy of irradiation. , 2007, Cancer research.

[45]  A. Sorisky,et al.  Protease inhibitors and adipocyte differentiation in cell culture , 1998, The Lancet.

[46]  P. Hruz,et al.  The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy* , 2000, The Journal of Biological Chemistry.

[47]  Thomas C. Chen,et al.  HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. , 2007, Cancer research.

[48]  R. Parker,et al.  Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease Inhibitors , 2005, Molecular Pharmacology.

[49]  M. Kazatchkine,et al.  Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. , 2001, The Journal of infectious diseases.

[50]  J. Berger,et al.  Inhibition of adipocyte differentiation by HIV protease inhibitors. , 1999, The Journal of clinical endocrinology and metabolism.

[51]  V. Wahn,et al.  Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy. , 1999, AIDS.

[52]  W. Chow,et al.  Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1 , 2006, Anti-cancer drugs.

[53]  W. Hohenberger,et al.  Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Christie M. Orschell,et al.  Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer , 2006, Clinical Cancer Research.

[55]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Schneider,et al.  Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. , 2001, The Journal of infectious diseases.

[57]  Robert H. Shoemaker,et al.  Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo , 2007, Clinical Cancer Research.

[58]  A. Sorisky,et al.  Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis , 2000, AIDS.

[59]  S. Grinspoon,et al.  Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. , 1999, The Journal of clinical endocrinology and metabolism.

[60]  R. Muschel,et al.  The Ras radiation resistance pathway. , 2001, Cancer research.

[61]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[62]  K. Nagashima,et al.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[63]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[64]  J. LoPiccolo,et al.  Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy , 2008, Autophagy.